Abstract
Aim:
There is a high incidence of the antiplatelet drug clopidogrel resistance (CR) in Asian populations. Because clopidogrel is a prodrug, polymorphisms of genes encoding the enzymes involved in its biotransformation may be the primary influential factors. The goal of this study was to investigate the associations of polymorphisms of CYP3A4, NR1I2, CYP2C19 and P2RY12 genes with CR in Chinese patients with ischemic stroke.
Methods:
A total of 191 patients with ischemic stroke were enrolled. The patients were treated with clopidogrel for at least 5 days. Platelet function was measured by light transmission aggregometry. The SNPs NR1I2 (rs13059232), CYP3A4*1G (rs2242480), CYP2C19*2 (rs4244285) and P2RY12 (rs2046934) were genotyped.
Results:
The CR rate in this population was 36%. The CYP2C19*2 variant was a risk factor for CR (*2/*2+wt/*2 vs wt/wt, OR: 2.366, 95% CI: 1.180–4.741, P=0.014), whereas the CYP3A4*1G variant had a protective effect on CR (*1/*1 vs *1G/*1G+*1/*1G, OR: 2.360, 95% CI: 1.247–4.468, P=0.008). The NR1I2 (rs13059232) polymorphism was moderately associated with CR (CC vs TT+TC, OR: 0.533, 95% CI: 0.286–0.991, P=0.046). The C allele in P2RY12 (rs2046934) was predicted to be a protective factor for CR (CC+TC vs TT, OR: 0.407, 95% CI: 0.191–0.867, P=0.018). In addition, an association was found between hypertension and CR (P=0.022).
Conclusion:
The individuals with both the CYP2C19*2 allele and hypertension are at high risk of CR during anti-thrombosis therapy. The CYP3A4*1G allele, P2RY12 (rs2046934) C allele and NR1I2 (rs13059232) CC genotype may be protective factors for CR. The associated SNPs studied may be useful to predict clopidogrel resistance in Chinese patients with ischemic stroke.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kelly RP, Close SL, Farid NA, Witers KJ, Shen L, Natanegara F, et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol 2012; 73: 93–105.
Boggon R, van Staa TP, Timmis A, Hemingway H, Ray KK, Begg A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction — a hospital registry - primary care linked cohort (MINAP-GPRD). Eur Heart J 2011; 32: 2376–86.
Perry CG, Shuldiner AR . Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet 2013; 58: 339–45.
Nguyen TA, Diodati JG, Pharand C . Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157–64.
Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ . Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246–51.
Ford NF . Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol 2009; 49: 506–12.
Hasan MS, Basri HB, Hin LP, Stanslas J . Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci 2013; 123: 143–54.
Jiang XL, Samant S, Lesko LJ, Schmidt S . Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet 2015; 54: 147–66.
Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92–9.
Wang XD, Deng XY, Chen J, Li JL, Chen X, Zhao LZ, et al. Single nucleotide polymorphisms of the pregnane X receptor gene in Han Chinese and a comparison with other ethnic populations. Pharmacology 2008; 81: 350–4.
Castano G, Burgueno A, Fernandez Gianotti T, Pirola CJ, Sookoian S . The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. Aliment Pharmacol Ther 2010; 31: 583–92.
Zhang B, Xie W, Krasowski MD . PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008; 9: 1695–709.
Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989–95.
Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013; 61: 872–9.
Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneetrithep B, et al. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One 2014; 9: e110188.
Rudez G, Bouman HJ, Van Werkum JW, Leebeek FW, Kruit A, Ruven HJ, et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2009; 2: 515–21.
Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 2013; 44: 1717–9.
Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244–7.
Liu Y, Liu N, Li W, Shao H, Zhi H, Li J . Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Pharmacology 2013; 91: 165–72.
Cuisset T, Morange PE, Alessi MC . Recent advances in the pharmacogenetics of clopidogrel. Hum Genet 2012; 131: 653–64.
Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849–57.
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363–75.
Loparev VN, Cartas MA, Monken CE, Velpandi A, Srinivasan A . An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents. J Virol Methods 1991; 34: 105–12.
Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA . Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657–66.
Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US . The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392–6.
Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, et al. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 2006; 7: 831–41.
Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R . Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999; 25: 15–9.
Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost 2007; 5: 75–81.
Du J, Yu L, Wang L, Zhang A, Shu A, Xu L, et al. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta 2007; 383: 172–4.
Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004; 23: 100.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26: 1895–900.
Choong E, Polari A, Kamdem RH, Gervasoni N, Spisla C, Jaquenoud Sirot E, et al. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol 2013; 33: 289–98.
Chew SC, Lim JS, Lee EJ, Chowbay B . Genetic variations of NR2A1 in Asian populations: implications in pharmacogenetics studies. Drug Metab Pharmacokinet 2013; 28: 278–88.
Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E . Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36: 169–81.
Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, et al. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010; 54: 5242–50.
Zoheir N, Abd Elhamid S, Abulata N, El Sobky M, Khafagy D, Mostafa A . P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting. Blood Coagul Fibrinolysis 2013; 24: 525–31.
Zee RY, Michaud SE, Diehl KA, Chasman DI, Emmerich J, Gaussem P, et al. Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. Atherosclerosis 2008; 197: 694–9.
Su JF, Hu XH, Li CY . Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with gene rs1045642 polymorphism. Exp Ther Med 2015; 9: 267–71.
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126–30.
Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008; 52: 1052–9.
Tantry US, Jeong YH, Gurbel PA . The clopidogrel-statin interaction. Circ J 2014; 78: 592–4.
Tirkkonen T, Heikkilä P, Vahlberg T, Huupponen R, Laine K . Epidemiology of CYP3A-mediated clopidogrel drug-drug interactions and their clinical consequences. Cardiovasc Ther 2013; 31: 344–51.
Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation a new drug-drug interaction. Circulation 2003; 107: 32–7.
Siller-Matula JM, Lang I, Christ G, Jilma B . Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557–63.
Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50: 291–5.
Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: Insights from the TRITON-TIMI 38 (Trialto Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In MyocardialInfarction 38). JACC Cardiovasc Interv 2013; 6: 1275–81.
Pelliccia F, Rosano G, Marazzi G, Vitale C, Spoletini I, Franzoni F, et al. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy — The PEARL randomized cross-over study. Eur J Pharmacol 2014; 725: 18–22.
Acknowledgements
This work was supported by the National Major Projects for Science and Technology Development from the Science and Technology Ministry of China (Grant No 2012ZX09506001-004) and the Fundamental Research Funds for the Central Universities (No 16ykpy14). The authors thank the Guangdong Provincial Hospital of Traditional Chinese Medicine for their cooperation.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Liu, R., Zhou, Zy., Chen, Yb. et al. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. Acta Pharmacol Sin 37, 882–888 (2016). https://doi.org/10.1038/aps.2016.41
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.41
Keywords
This article is cited by
-
Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs
Cardiovascular Drugs and Therapy (2024)
-
The stent thrombosis in Belgium (STIB) scoring system reliability in Indonesia patients and the modified STIB scoring (M-STIB)
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2023)
-
Association between P2Y1 and P2Y12 polymorphisms and acute myocardial infarction and ADP-induced platelet aggregation
BMC Cardiovascular Disorders (2023)
-
Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke
Scientific Reports (2023)
-
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients
Molecular Diagnosis & Therapy (2021)
